Skip to Content

Nordimet

Active Substance: methotrexate
Common Name: methotrexate
ATC Code: L01BA01
Marketing Authorisation Holder: Nordic Group B.V.
Active Substance: methotrexate
Status: Authorised
Authorisation Date: 2016-08-18
Therapeutic Area: Arthritis, Rheumatoid Arthritis, Psoriatic Psoriasis Arthritis, Juvenile Rheumatoid
Pharmacotherapeutic Group: Antineoplastic agents

Therapeutic Indication

Nordimet is indicated for the treatment of:

  • active rheumatoid arthritis in adult patients,
  • polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,
  • severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, psoralens and ultraviolet A (PUVA), and retinoids, and severe psoriatic arthritis in adult patients.

What is Nordimet and what is it used for?

Nordimet is a medicine used to treat the following inflammatory conditions:

  • active rheumatoid arthritis, a disease causing inflammation in joints;
  • severe juvenile idiopathic arthritis (JIA), a joint disease in children, when medicines known as NSAIDs (non-steroidal anti-inflammatory drugs) have not worked well enough;
  • severe disabling psoriasis, a disease causing red, scaly patches on the skin, when other treatments have not worked well enough;
  • severe psoriatic arthritis, inflammation of the joints that occurs in patients with psoriasis.

Nordimet is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ (in this case Lantarel FS) containing the same active substance (methotrexate). The difference between Nordimet and Lantarel FS is that Nordimet is available in more strengths.

How is Nordimet used?

Nordimet is available as a solution of various strengths and should be injected under the skin once a week on the same day each week. The dose depends on the condition it is being used to treat and how the patient responds to treatment and, in the case of children, on the body surface area. In most cases, Nordimet is used for long-term treatment.

Getting the dose or timing of injections wrong can lead to serious side effects. Doctors prescribing this medicine must have experience with methotrexate and understand how it works. The medicine can only be obtained with a prescription.

For more information on how to use Nordimet, see the package leaflet.

How does Nordimet work?

The active substance in Nordimet, methotrexate, stops cells from growing too fast by interfering with the production of DNA. The reason that this action helps patients with arthritis and psoriasis is not completely understood, but the benefits of methotrexate are thought to be due to its ability to reduce inflammation and suppress an overactive immune system.

How has Nordimet been studied?

The company provided data from the published literature on methotrexate. No additional studies were needed as Nordimet is a hybrid medicine that is given by injection and contains the same active substance as the reference medicine, Lantarel FS.

What benefits of Nordimet have been shown in studies?

Because Nordimet has the same composition as the reference medicine, Lantarel FS, its benefits and risks are taken as being the same as those of Lantarel FS.

Why is Nordimet approved?

The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that Nordimet has been shown to be comparable to reference medicine. Therefore, the CHMP’s view was that, as for reference medicine, the benefits of Nordimet outweighs it risks. The Committee recommended that Nordimet be approved for use in the EU.

What measures are being taken to ensure the safe and effective use of Nordimet?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nordimet have been included in the summary of product characteristics and the package leaflet.

Other information about Nordimet

The European Commission granted a marketing authorisation valid throughout the European Union for Nordimet on 18 August 2016.

For more information about treatment with Nordimet, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide